Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by Surgery
Key facts
- Who runs it
- M.D. Anderson Cancer Center
- Where
- Houston, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Phase 2
- People taking part
- 29 people enrolled
- Started
- 23 Sept 2016
- Ended
- 5 Dec 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Chemotherapy
- Laboratory Biomarker Analysis
- Metastasectomy
- Quality-of-Life Assessment
- Therapeutic Conventional Surgery
- Record updated
- 17 February 2026
- Why it stopped
- \< 75% participation
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Patients with synchronous or metachronous diagnosis of resectable liver metastases by computed tomography (CT) or magnetic resonance imaging (MRI) of the abdomen; Patients requiring percutaneous or intraoperative ablation of liver metastases < 2 cm in size are eligible; Patients who underwent prior liver resection or ablation for colorectal liver metastases are eligible
- Patients previously treated with systemic chemotherapy and/or biologic agents for colorectal cancer are eligible
- The primary tumor in the colon or rectum may be intact or resected
- Low-volume lung metastases are defined as solid pulmonary nodules < 2 cm with non-spiculated contours, no benign-appearing calcifications, and =< 14 in number, diagnosed by computed tomography of the chest or positron emission tomography (PET)
- Lung metastases will be unresectable due to anatomic location, distribution, or patients' comorbidities, as determined by review of imaging by a faculty member in the Department of Thoracic \& Cardiovascular Surgery
- Patients must sign a study-specific consent form
- Patients will undergo CT imaging of the chest, abdomen, and pelvis to evaluate lung and liver metastases within 60 days of registration; for patients who cannot tolerate CT contrast or have hepatic steatosis that reduces the sensitivity of CT, MRI of the liver will be performed
Who cannot take part
- Planned stereotactic body radiation therapy (SBRT) for the pulmonary metastases
- Radiographic evidence of disease other than liver and lungs, with the exception of mediastinal lymph nodes < 2 cm and hepatoduodenal ligament lymphadenopathy, diagnosed by computed tomography, magnetic resonance imaging, or positron emission tomography
- Serum bilirubin >= 2 mg/dL
- Platelet count < 50,000/uL
- Eastern Cooperative Oncology Group (ECOG) performance status of 3-4
- Patient refusal to participate in randomization
- Pregnant women are excluded from this study
Where in United States
- M D Anderson Cancer CenterHouston, United States
About the trial
What the trial wants to find out
This randomized phase II trial studies how well liver surgery and chemotherapy compared to chemotherapy alone work in treating patients with colorectal cancer that has spread to the liver (liver metastases) that can be removed by surgery and that has spread to the lungs (lung metastases) that cannot be removed by surgery. Liver surgery removes a portion of the liver affected by the tumor. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Liver surgery and chemotherapy may work better than chemotherapy alone in treating patients with colorectal cancer which has spread to the liver and lungs.
The 2 groups in the trial
- Group I (surgery, chemotherapy)Treatment being tested
Patients undergo hepatectomy and receive chemotherapy at the discretion of treating oncologist. Patients whose lung tumors become able to be removed by surgery with chemotherapy may undergo lung metastasectomy.
Treatment: Chemotherapy, Laboratory Biomarker Analysis, Metastasectomy, Quality-of-Life Assessment, and Therapeutic Conventional Surgery
- Group II (chemotherapy)Existing treatment, for comparison
Patients receive chemotherapy at the discretion of the treating oncologist. Patients whose lung tumors become able to be removed by surgery with chemotherapy may undergo lung metastasectomy.
Treatment: Chemotherapy, Laboratory Biomarker Analysis, Metastasectomy, and Quality-of-Life Assessment
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Randomized Controlled Phase II Trial of Liver Resection Versus No Surgery in Patients With Liver and Unresectable Pulmonary Metastases From Colorectal Cancer
- Record updated
- 17 February 2026